U.S. President Donald Trump attends a cabinet meeting at the White House in Washington, D.C., U.S., December 2, 2025. REUTERS/Brian Snyder

After President Donald Trump returned to the White House on January 20, his administration aggressively downsized a long list of federal government agencies with the help of the Department of Government Efficiency (DOGE) and its then-leader, Tesla/SpaceX/X.com head Elon Musk. Trump claimed that his goal was reducing "waste, fraud and abuse," but critics of the Trump Administration/DOGE cuts argued that they were robbing the agencies of crucial personnel they need in order to function properly — from the U.S. Social Security Administration (SSA) to the National Weather Service (NWS) to the Internal Revenue Service (IRS).

Another agency that has been suffering chaos during Trump's second presidency is the U.S. Food and Drug Administration (FDA).

In an article published on December 4, Axios' Pete Sullivan describes the FDA departures that are contributing to instability at the agency.

"Another abrupt departure of a high-ranking Food and Drug Administration official is raising alarm about a brain drain that could mean new drugs take longer to reach the public," Sullivan reports. "Why it matters: Biotech and pharmaceutical companies rely on the FDA for dependable guidance as they spend huge sums developing new treatments. The American public needs the agency to ensure treatments are safe and effective…. Driving the news: The latest uproar surrounds the unexpected departure of Richard Pazdur, a respected oncologist who just three weeks ago became the fourth person to direct the FDA's drug center this year."

Sullivan adds, "Pazdur's appointment had helped calm nerves to some degree within industry after months of turmoil. But now, executives and even former FDA commissioners are publicly questioning the agency's direction."

One of the people who is sounding the alarm about the FDA is Biotechnology Innovation Organization CEO John Crowley.

Crowley told Axios, "This constant turmoil is undermining America's leadership in biotechnology, creating unprecedented regulatory instability and unpredictability, and risks ceding this critical sector to China."

According to Sullivan, "morale" has "plummeted" at the FDA.

A former FDA staffer, interviewed on condition of anonymity, told Axios, "They don't talk to each other. They go to the bathroom, they come (back), they shut their door."

Read Peter Sullivan's full article for Axios is available at this link.